Tricida, Inc., is a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer (also known as TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD). Metabolic acidosis is a chronic condition commonly caused by CKD that is believed to accelerate the progression of CKD, increase the risk of muscle wasting and cause the loss of bone density.
Learn More
CKD is a serious condition characterized by the gradual loss of essential kidney functions over time. In patients with CKD, normal fluid and electrolyte balance can no longer be maintained…
Learn More
Our investigational drug, veverimer (also known as TRC101), is a novel, non-absorbed polymer that is designed to bind…
Learn More
Tricida to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference
Learn More
Tricida, Inc., is a pharmaceutical company focused on the development…
Learn More